Prostate Cancer Canada
10
1
3
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.0%
1 terminated/withdrawn out of 10 trials
75.0%
-11.5% vs industry average
10%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Role: collaborator
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
Role: collaborator
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Role: collaborator
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Role: collaborator
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Role: collaborator
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
Role: collaborator
Towards Optimal Prescription of Chemotherapy in Prostate Cancer
Role: collaborator
Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca
Role: collaborator
PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures
Role: collaborator
18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer
Role: collaborator
All 10 trials loaded